| BACHEM N -B- | 419.50 / +3.71% |
| Date/Time | 04/09 / 17:30 |
| Chg. / Chg.(%) | 15.00 / +3.71% |
| Bid | - / 17 |
| Ask | 422.00 / 150 |
| Open | 407.50 |
| Previous Close | 404.50 |
| High | 423.00 |
| Low | 407.00 |
| Volume [CHF] | 5,228,067.75 |
| Volume [Units] | 12,478 |
| Price fixings | 574 |
| ISIN | CH0012530207 |
| Security | BANB |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 379.50 |  |
|
| SIX Swiss Ex.. | 419.50 |  |
12,478 |
| London Inter.. | 419.50 | |
2,570 |
| Cboe Europe .. | 418.00 | |
1,229 |
| Cboe Europe .. | 418.50 | |
947 |
| Turquoise | 418.00 | |
516 |
| Nasdaq Other.. | 418.0000 | 48 | |
| Frankfurt | 115.0000 | 0 | |
| Berlin | 116.20 | 0 | |
| München | 114.80 | 0 | |
| Hamburg | 114.80 | 0 | |
| EUREX | Options | ||
News
- Bachem chooses iland and Veeam to spearhead data continuity and cloud backup transition
03/16/2021 / 11:00 - GlobeNewswire - Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
05/14/2020 / 07:00 - GlobeNewswire - Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
05/04/2020 / 14:30 - GlobeNewswire - Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial
04/28/2020 / 15:24 - GlobeNewswire - Vaccine Contract Manufacturing Market, 2030 - Market is Anticipated to Generate Revenues Worth USD 100 Billion by 2025
10/04/2019 / 10:05 - GlobeNewswire
Real-time